Twin blows spur a crisis of confidence in RNAi

In the wake of Roche's stunning decision to write off its $500 million investment in RNAi work, some of the analysts who cover companies in the field appear to be losing confidence in what once was widely viewed as one of the most compelling new development categories since antibodies came along.

"The momentum now seems to be heading a bit against RNAi," Alan Carr, an analyst at Needham & Company, says to Nature. Case in point: Deal-making is drying up. "There was a wave of interest earlier on and it's just not there now."

Josh Schimmer, an analyst at Leerink Swann, even suggests that while RNAi pioneer Alnylam has a "very interesting drug at this's premature to say they have a very promising platform."

Alnylam was forced to chop some 50 workers recently after Novartis ($NVS) declined to extend its ambitious partnership in the field. Alnylam CEO John Maraganore, though, is as bullish about the future as he's ever been. "We're feeling pretty damn good about where things are right now."

- here's the article from Nature

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.